Regeneron Pharmaceuticals, Inc. REGN announced that the European Commission (EC) has approved a label expansion of its PCSK9 inhibitor, Praluent. The drug’s label has been expanded to reduce ...
Regeneron Pharmaceuticals, Inc. REGN announced that the FDA extended the approval of the cholesterol drug Praluent’s (alirocumab) label. The regulatory body approved the drug as an adjunct to diet and ...
European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results